主页 > 医学动态 >
【bio-news】生长因子预示乳腺癌的预后差
The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.
"These findings come at a critical time," said Dr. Adrian Lee, associate professor in the Lester and Sue Smith Breast Center at BCM. "Our goal is to identify biomarkers that will help predict which patients will respond to therapy against insulin-like growth factor. Several inhibitors of the IGF pathway are in patient studies right now. There's a large movement to understand which patients will respond to these drugs. This is a step toward that goal"
In this study, Lee and his colleagues stimulated breast cancer cells with IGF-I in the laboratory and defined how more than 800 genes in the cells responded to the growth factor. They then examined samples of patient breast tumors with this "gene signature" and correlated the gene signatures with the fate of the patients.
"We have technology now to allow us to globally assess what IGF is doing in breast cancer at the whole gene expression level," said Lee. "This is one of the first studies to do that. We know that IGF is bad in cancer, but now we can globally understand it in a more comprehensive manner. It could lead to finding biomarkers for patients response" to breast cancer treatments.
"We found that IGF-I is a major regulator of cell growth and cell survival," said Lee. "It also regulates DNA repair."
This has major implications for anti-cancer treatments that seek to cause DNA damage and tumor cell death.
"If you have something regulating DNA repair, you want that turned off," said Lee.
They found that tumors in which IGF (insulin-like growth factor) affected the way in which genes were activated or translated into messages were more aggressive and more likely to grow. They also found that the effect of IGF was independent of whether the tumor was affected by estrogen or not.
"This is very important," said Lee. "Once patients are resistant to hormone treatment (as with tamoxifen), their treatment options are limited. A treatment that inhibited receptors for IGF might give them another option."
Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin® or an aromatase inhibitor that blocks estrogen production) in postmenopausal women. One group of women take the combination and the other takes exemestane.
Bioinformatics – the ability to analyze large amounts of data – proved key to the study, said Lee. In fact, the first author, Dr. Chad J. Creighton of BCM, is a bioinformatician, said Lee.
Others who took part in this research include Angelo Casa, ZaWaunyka Lazard, Shixia Huang, Anna Tsimelzon, Susan G. Hilsenbeck and C. Kent Osborne, all of BCM.
Funding for this work came from the National Institutes of Health and the Baylor College of Medicine/AstraZeneca Alliance.
http://www.sciencedaily.com/releases/2008/08/080829114911.htm 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Growth Factor Predicts Poor Outcome In Breast Cancer
生长因子能预测乳腺癌的预后不良
The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.
乳腺癌细胞对胰岛素样生长因子1(IGF-I)的反应能预测那些对治疗反应不佳的侵袭性肿瘤， Baylor医科大学的学者在本期临床肿瘤学杂志中发表。该发现促使人们根据肿瘤自身性质饿不同而采取个体化治疗方法。
"These findings come at a critical time," said Dr. Adrian Lee, associate professor in the Lester and Sue Smith Breast Center at BCM. "Our goal is to identify biomarkers that will help predict which patients will respond to therapy against insulin-like growth factor. Several inhibitors of the IGF pathway are in patient studies right now. There's a large movement to understand which patients will respond to these drugs. This is a step toward that goal"
BCM的Lester&Sue Smith乳腺中心的Adrian Lee博士说道：“这些发现的时机很重要。我们的目标是找出哪些生物学标记能帮助我们预测哪些病人将对胰岛素样生长因子的治疗敏感。我们正在住院病人中进行IGF途径的几个抑制物的研究。这对于理解哪些病人将对所给药物敏感是至关重要的。这是实现以上目标的其中一步。”
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-25 05:11
医学,生命科学网